Eton Pharmaceuticals, Inc. (ETON) P/E Ratio History
UndervaluedTrading at 41.4x vs 5Y avg 68.4x · 25th percentile · Below historical baseline · Data 2023–2026
Loading P/E history...
P/E Ratio Analysis
As of November 19, 2026, Eton Pharmaceuticals, Inc. (ETON) trades at a price-to-earnings ratio of 41.4x, with a stock price of $61.99 and trailing twelve-month earnings per share of $1.50.
The current P/E is 40% below its 5-year average of 68.4x. Over the past five years, ETON's P/E has ranged from a low of 34.0x to a high of 97.7x, placing the current valuation at the 25th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.7x, ETON trades at a 68% premium to its sector peers. The sector includes 252 companies with P/E ratios ranging from 0.0x to 187.0x.
Relative to the broader market, ETON commands a significant premium over the S&P 500 median P/E of 21.7x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ETON DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ETON Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ETON P/E vs Peers
Rare Disease Commercial Leaders peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 25.9 | - | -22% | |
| $4B | 7.9Lowest | - | +10833%Best | |
| $7B | 51.6 | - | -33% | |
| $1B | 14.2 | 1.11Best | +105% | |
| $127B | 26.9 | - | +49% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ETON Historical P/E Data (2023–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $51.49 | $1.51 | 34.0x | -50% |
| FY2026 Q2 | - | $36.20 | $0.38 | 94.1x | +38% |
| FY2024 Q1 | Mar 31 2024 | $3.75 | $0.04 | 97.7x | +43% |
| FY2023 Q3 | Sep 30 2023 | $4.17 | $0.09 | 47.7x | -30% |
Average P/E for displayed period: 68.4x
ETON Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ETON — Frequently Asked Questions
Quick answers to the most common questions about buying ETON stock.
What is ETON's P/E ratio?
Eton Pharmaceuticals, Inc. (ETON) trailing twelve-month P/E ratio is 41.4x, based on TTM diluted EPS of $1.50. The 5-year average P/E is 68.4x and the historical range spans 34.0x to 97.7x.
Is ETON stock overvalued or undervalued?
ETON trades at 41.4x P/E, below its 5-year average of 68.4x. At the 25th percentile of its historical range (34.0x–97.7x), the stock is priced at a discount to its own history.
Is ETON stock expensive?
No, ETON is not expensive on a historical basis. The current P/E of 41.4x is below the 5-year average of 68.4x and sits at the 25th percentile of its valuation range.
What is ETON's historical P/E range?
Over the past 5 years, ETON's P/E ratio has ranged from 34.0x to 97.7x, with a median of 94.1x and an average of 68.4x. The current P/E of 41.4x places the stock at the 25th percentile of this range. Full historical data spans 2023–2026.
How does ETON's P/E compare to the S&P 500?
ETON trades at 41.4x P/E versus the S&P 500 median of 21.7x. The 91% premium to the market typically reflects higher expected earnings growth or quality.
How does ETON's valuation compare to Healthcare peers?
Eton Pharmaceuticals, Inc. P/E of 41.4x compares to the Healthcare sector median of 24.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ETON's PEG ratio?
ETON PEG ratio is N/A, based on a P/E of 41.4x and EPS growth of -13.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ETON's earnings yield?
ETON earnings yield is 2.42%, the inverse of its 41.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.